Products

Insulin Aspart

Product Information

Cat #

MFTP-135

CAS No.

116094-23-6

Enzyme Commission Number

Product Overview

Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analog has increased charge repulsion, which prevents the formation of hexamers, to create a faster-acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor.

Features

Ready-to-use product, accelerating research progress, enhancing application performance.

Method

Technology

Synonyms

Type

Function

Applications

Pharmaceutical Industry

Storage

Storage Buffer

Shelf Life

Strains

Yeast

Source

Appearance

Molecular Weight

Color / Form

Instruction

Enzyme Class

Production Methods

Fermentation

Activity

Specific Enzyme Activity

Purity

> 99%

Unit Definition

Amino Acids Sequence

WARNINGS

Shipping

Timely shipping by optional means

Formula

Reaction

Recommendation

Species Reactivity

Contents

Compatibility

Melting Point

Final Titre

≧2.5g/L(50L)

Fermentation Time

Recovery Yield

15-16%

Starting Material

Specification

Standard and Custom Specifications

Substrates

Concentration

Usage And Dosage

Description

Insulin aspart is a fast-acting insulin analog marketed . It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream.

For Research Use Only.

Have a question? Get a Free Consultation